Introduction {#s1}
============

A biomarker in medicine is a measurable parameter that can be used to assess a physiological or pathological state of an organism. Proteins in the blood stream can be used as biomarkers. Cardiovascular biomarkers are used to assess the cardiac and circulatory situation in adult medicine. These same biomarkers are also relevant in perinatal maternal and fetal physiology. Cardiovascular biomarkers can act as physiological regulators in the perinatal setting. Therefore, in the field of cardiovascular biomarkers, there is an interesting overlap between neonatology, obstetrics, and cardiology. Cardiovascular biomarkers may help to understand fetal and maternal physiology in pregnancy and during the perinatal transition period. Even though the fetal and maternal circulation is regulated independently in pregnancy and during delivery, an effect of fetal biomarkers on maternal physiology and vice versa has been postulated. Copeptin is a C-terminal component of pre-pro-arginine vasopressin and is secreted simultaneously with vasopressin. Vasopressin plays an important role in circulatory and stress regulation in maternal and fetal responses to labor ([@B1], [@B2]). Natriuretic peptides are of interest in the perinatal setting because they have important renal and cardiovascular effects during intrauterine and extrauterine life ([@B3]--[@B7]). During intrauterine life, the fetus needs to maintain sufficient urine production to provide amniotic fluid (AF). This is important for lung development. Natriuretic peptides are elevated in pregnancy ([@B3]) and may thus help to maintain sufficient fetal urine output. After birth, clearing fluid from the lungs to establish sufficient respiration is important. Vasopressin helps to clear pulmonary fluid ([@B8]). This indicates that biomarkers representing different physiological actions, such as natriuretic peptides and vasopressin/copeptin, are relevant for sufficient pulmonary function of newborns. Therefore, a combined analysis of several biomarkers ([@B1]--[@B11]) in the perinatal context could be useful for further determining perinatal/fetal and maternal physiology.

In adult medicine, cardiovascular biomarkers, such as N-terminal pro-brain natriuretic peptide (NTproBNP) and midregional pro-atrial natriuretic peptide (MRproANP), are mentioned in current guidelines on acute and chronic heart failure as diagnostic tools ([@B12], [@B13]). Large population-based studies combining several cardiovascular biomarkers ([@B14], [@B15]) are used as an approach to identify optimal cut-off values for individual biomarkers and diseases.

The authors of a recent editorial discussed the use of biomarkers in neonatology and expressed the need to establish reference values for biomarkers in different body fluids ([@B16]). This study aimed to analyze cardiovascular biomarkers in combined samples of amniotic fluid (AF), arterial umbilical blood (UAB), venous umbilical blood (UVB), and maternal blood (MATB) in the perinatal setting at the time of delivery. To the best of our knowledge, this is the first study providing a linked analysis of biomarkers in these four body fluids in individual pregnancies. The examined biomarkers were chosen on the basis of a previous study ([@B17]), and they are clinically used in adult medicine and relevant in the perinatal setting.

Materials and Methods {#s2}
=====================

Study Design
------------

The primary aim of the study was to measure and correlate cardiovascular biomarker levels between different fetal and maternal fluid compartments at the time of delivery. Secondary aims were to establish reference values and to identify factors affecting biomarker levels. The examined fluids were AF, UAB, UVB, and MATB. The examined biomarkers were midregional pro-adrenomedullin (MRproADM), MRproANP, brain natriuretic peptide (BNP), NTproBNP, copeptin, and high-sensitive troponin I (hsTnI). The study cohort was recruited from healthy term or late preterm pregnancies at the time of delivery. The study was conducted as a prospective, single-center, cross-sectional, observational study at the University Medical Center Hamburg-Eppendorf (UKE). Patients with consecutive term or late preterm pregnancies with delivery at the UKE, for whom antenatal agreement to participate in the study was obtained, were included. Patients with pregnancies with maternal conditions, such as assisted reproduction, gestational diabetes, HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), and preeclampsia, were not excluded. Patients with pregnancies with fetal cardiac or chromosomal anomalies were excluded from the study. The study database did not provide maternal or fetal follow-up data. The study was approved by the local ethics committee of the Chamber of Physicians Hamburg, Germany. This study combined data with a previously published database ([@B17]). The present study tripled the sample size and added biomarker levels in UAB and AF.

Patients
--------

Matched samples of AF, UAB, UVB, and MATB were taken at the time of delivery with parental consent. Umbilical cord blood samples that were taken from the placenta represented perinatal, rather than purely fetal, blood samples because they reflected the status of the child at the time of cord clamping. For reasons of simplicity and to distinguish the mother and child, we chose the term "fetal" rather than "perinatal" throughout the text for cord blood samples. The study cohort included 189 neonates and their mothers (*n* = 170) ([Table 1](#T1){ref-type="table"}). Of the 189 neonates, 162 were full-term neonates, 129 were born by primary cesarean section, and 151 were singletons. There were 15 sets of twins and two sets of triplets. There were 93 male neonates. In the total cohort of 189 neonates, there were the following maternal conditions: four cases of HELLP (hemolysis, elevated liver enzymes, low platelets) or preeclampsia, 17 cases of maternal (gestational) diabetes (3/17 insulin-dependent), 11 cases of assisted reproduction, and five cases of oligohydramnious. A sample cohort subset of singleton, full-term, primary cesarean deliveries excluding one case of HELLP was chosen as the database for calculating reference values. In this group of 91 pregnancies ([Table 2](#T2){ref-type="table"}), there were 11 cases of maternal (gestational) diabetes (2/11 insulin dependent) and two cases of assisted reproduction.

###### 

Sample characteristics for the total cross sectional study cohort (*n* = 189 neonates).

  **Parameter**                           **Mean**   **Median**   **SEM**   **SD**   **Minimum**   **Maximum**
  --------------------------------------- ---------- ------------ --------- -------- ------------- -------------
  Birth weight \[kg\]                     3.191      3.280        0.051     0.707    0.807         5.305
  Birth length \[cm\]                     50.19      51.00        0.30      4.09     30.50         56.00
  Head circumference \[cm\]               34.83      35.00        0.20      2.75     25.00         54.50
  Apgar 1 min                             8.78       9.00         0.07      0.92     3.00          10.00
  Apgar 5 min                             9.62       10.00        0.06      0.82     6.00          10.00
  Apgar 10 min                            9.85       10.00        0.04      0.49     7.00          10.00
  Gestational age \[weeks\]               38.39      38.71        0.16      2.18     27.57         41.71
  Umbilical arterial pH                   7.30       7.32         0.01      0.08     7.03          7.44
  Fetal arterial base excess \[mmol/l\]   −1.87      −0.70        0.29      3.89     −19.00        4.50
  Maternal age \[years\]                  33.70      34.00        0.36      4.99     21.00         46.00
  Maternal weight \[kg\]                  82.45      80.00        1.11      14.73    50.00         142.50

###### 

Sample characteristics: singleton term neonates (*n* = 91 neonates) delivered by elective cesarean section used for reference value calculation.

  **Parameter**                           **Mean**   **Median**   **SEM**   **SD**   **Minimum**   **Maximum**
  --------------------------------------- ---------- ------------ --------- -------- ------------- -------------
  Birth weight \[kg\]                     3.483      3.400        0.051     0.490    1.990         4.825
  Birth length \[cm\]                     51.52      51.00        0.23      2.17     45.50         56.00
  Head circumference \[cm\]               35.41      35.00        0.15      1.44     30.50         39.50
  Apgar 1 min                             9.09       9.00         0.06      0.57     6.00          10.00
  Apgar 5 min                             9.82       10.00        0.06      0.55     7.00          10.00
  Apgar 10 min                            9.97       10.00        0.02      0.18     9.00          10.00
  Gestational age \[weeks\]               38.86      38.86        0.06      0.60     37.00         41.00
  Umbilical arterial pH                   7.33       7.33         0.00      0.04     7.20          7.44
  Fetal arterial base excess \[mmol/l\]   0.02       −0.10        0.20      1.88     −4.90         4.50
  Maternal age \[years\]                  34.41      36.00        0.52      4.93     22.00         43.00
  Maternal weight \[kg\]                  82.95      82.00        1.57      14.63    57.00         124.00

Laboratory Measurements
-----------------------

Blood samples were processed within an average time of 2 h, centrifuged, aliquoted, and frozen at −80°C. Laboratory analyses for each biomarker were performed with duplicate analysis of stored samples using commercially available kits. MR-proADM levels were measured in EDTA plasma with a fluoroimmunoassay (BRAHMS MR-proADM KRYPTOR; BRAHMS GmbH, Hennigsdorf, Germany). The analytical limit of detection (LoD) of this assay was 0.08 nmol/L. The intra-assay coefficient of variation (CV) was 4.23% and the inter-assay CV was 10.49%. MRproANP levels were measured in EDTA plasma with a fluoroimmunoassay (BRAHMS MR-proANP KRYPTOR; BRAHMS GmbH) (LoD: 6.0 pmol/L, intra-assay CV: 4.76%, inter-assay CV: 2.39%). BNP levels were measured by immunoassay in serum samples (ARCHITECT i2000SR; Abbott Diagnostics, Abbott Park, IL, USA) (LoD: 10 pg/mL, intra-assay CV: 5.7%, inter-assay CV: 20.68%) (as stated by the manufacturer). NT-proBNP levels were measured in serum samples using the Elecsys proBNP II assay and the ELECSYS 2010 was used for detection (ECLIA; Roche Diagnostics, Mannheim, Germany) (LoD: 5 ng/L, intra-assay CV: 0.97 and 5.15% on two separate occasions, inter-assay CV: 5.86%). Copeptin was levels were measured in EDTA plasma with a fluoroimmunoassay (BRAHMS Copeptin us KRYPTOR; BRAHMS GmbH) (LoD: 4.8 pmol/L, intra-assay CV: 2.33%, inter-assay CV: 4.48%). Levels of hsTnI were assessed in serum samples (ARCHITECT STAT highly sensitive troponin I immunoassay; Abbott Diagnostics) (LoD: 1.9 ng/L, inter-assay CV: 2.23, 2.36, and 5.58% on separate occasions, inter-assay CV: 3.66%).

Data Collection and Statistics
------------------------------

Demographic data and laboratory results were analyzed using SPSS software (SPSS 20.0® IBM, Armonk, NY, USA) and R software (R Foundation for Statistical Computing, version 3.5.2 \[2018-12-20\]; Vienna, Austria, <https://www.R-project.org/>). The mean, standard error of the mean (SEM), standard deviation (SD), median, and interquartile range (IQR) were calculated. Percentiles are shown for individual biomarkers and different body fluid components in full-term, singleton, cesarean deliveries. Nonparametric tests (Spearman\'s correlation, Wilcoxon rank test) were used as appropriate. The relationships of individual biomarkers within the different body fluid compartments in individual mother--child pairs and between the different biomarkers were analyzed and modeled. The effect of demographic factors (gestational age, delivery mode, and multiple pregnancies) was tested. Multivariate ANOVA analysis of the factors of biomarkers, source of biomarkers (i.e., different body fluids), and delivery mode was performed. ANOVA on the effect of maternal pathology (HELLP, preeclampsia, maternal \[gestational\] diabetes, and assisted reproduction) was performed. The significance level was set to *p1* \< 0.05.

Results {#s3}
=======

Analysis of Factors Affecting Biomarker Levels
----------------------------------------------

Multivariate ANOVA of biomarkers, the source of biomarkers, and delivery mode showed that these factors were all relevant and should thus be analyzed separately. Univariate ANOVA of the factors of maternal (gestational) diabetes and assisted reproduction did not show a significant effect on biomarker levels in the sample subgroup of full-term singletons born by elective cesarean section (chosen for reference value calculation) ([Table 2](#T2){ref-type="table"}). There was, however, an effect of "diabetes" on hsTnI in UAB (*p* \< 0.01) and MRproADM in AF (*p* = 0.43). Univariate ANOVA of the factor HELLP was significant for all maternal biomarkers (*p* \< 0.01), except for hsTnI (*p* = 0.08) and Copeptin (*p* = 0.92).

The effects of gestational age, labor, and multiple pregnancies on biomarker levels are shown in [Table 3](#T3){ref-type="table"}. The effect of gestational age on biomarker levels is shown in [Supplements 1](#SM1){ref-type="supplementary-material"}--[6](#SM5){ref-type="supplementary-material"}. Differences in the biomarkers between elective cesarean deliveries and deliveries by labor were observed. The effect of mode of delivery on the biomarker correlations is shown in [Supplements 7](#SM7){ref-type="supplementary-material"}, [8](#SM8){ref-type="supplementary-material"}.

###### 

Cardiovascular biomarkers in different body fluids in singleton term deliveries delivered by elective cesarean section.

  **Biomarker**         **Body Fluid**   **Mean**   **SEM**   **Median**   **IQR**   **N**
  --------------------- ---------------- ---------- --------- ------------ --------- -------
  MRproADM \[nmol/L\]   UAB              0.96       0.07      0.88         0.20      22
                        UVB              0.97       0.02      0.95         0.18      65
                        AF               2.84       0.20      2.80         1.18      37
                        MATB             1.17       0.05      1.10         0.54      77
  MRproANP \[pmol/L\]   UAB              221.72     10.83     214.23       91.38     48
                        UVB              231.09     8.33      216.03       86.15     86
                        AF               3.00       1.47      0.00         3.82      37
                        MATB             55.37      2.74      50.67        26.81     87
  BNP \[pg/mL\]         UAB              24.13      4.74      14.60        25.18     21
                        UVB              27.59      3.58      22.08        18.91     66
                        AF               8.34       0.92      7.15         6.01      38
                        MATB             12.79      1.84      6.20         18.23     77
  NTproBNP \[pg/ml\]    UAB              853.34     64.59     765.48       555.24    48
                        UVB              979.43     60.95     816.45       675.71    86
                        AF               84.74      7.06      72.03        55.58     37
                        MATB             57.27      5.12      44.40        43.94     87
  Copeptin \[pmol/L\]   UAB              188.90     44.41     46.17        290.42    46
                        UVB              24.51      7.22      5.54         9.08      87
                        AF               12.85      1.94      9.97         7.44      38
                        MATB             8.46       1.25      4.61         4.59      86
  HsTnI \[pg/mL\]       UAB              16.44      6.91      6.20         4.25      45
                        UVB              14.30      4.84      5.60         5.01      86
                        AF               1.13       0.24      0.45         1.73      38
                        MATB             3.08       0.24      2.50         2.40      87

*UVB, umbilical venous blood; UAB, umbilical arterial blood; AF, amniotic fluid; MATB, maternal blood. The database consisted of n = 91 neonates and their mothers*.

Comparison of Biomarker Levels in Different Body Fluids
-------------------------------------------------------

The distribution of biomarkers in the fluid compartments of AF, MATB, UAB, and UVB is shown in [Figure 1](#F1){ref-type="fig"}. [Figure 2](#F2){ref-type="fig"} shows estimated mean relative biomarker levels in the different body fluids for each analyzed biomarker. The highest levels of MRproADM were observed in AF, followed by MATB, and the lowest levels were in fetal blood. Levels of the natriuretic peptides MRproANP, BNP, and NTproBNP were higher in fetal than in MATB. Copeptin levels in UAB were higher than those in UVB. All biomarkers (except MRproADM) were found in higher concentrations in fetal blood than in MATB.

![Graphs showing the measured biomarkers in amniotic fluid (AF), maternal blood (MATB), umbilical arterial blood (UAB), and umbilical venous blood (UVB). The individual color coded lines represent individual combined linked sample sets related to individual deliveries. Each line represents linked biomarker levels in an individual pregnancy. Green lines (elective) represent linked samples resulting from elective cesarean section. Orange lines (non-elective) represent non-elective deliveries with exposure to labor (i.e., vaginal delivery and secondary cesarean section). The database consisted of 189 neonates and their mothers.](fped-07-00271-g0001){#F1}

![Distribution of biomarkers in color coded body fluid components of amniotic fluid (AF), maternal blood (MATB), umbilical arterial blood (UAB), and umbilical venous blood (UVB). Data are expressed as the standardized mean and SEM of the different biomarkers in relation to an estimated modeled mean. Data distinguish between elective and non-elective deliveries. Solid lines and dots represent elective cesarean deliveries (elective). Dashed lines and triangles represent deliveries with exposure to labor (i.e., vaginal delivery or secondary cesarean section, \[non-elective\]). The database consisted of 189 neonates and their mothers.](fped-07-00271-g0002){#F2}

Bivariate Spearman\'s correlations for the six examined biomarkers (MRproADM, MRproANP, BNP, NTproBNP, copeptin, hsTnI) were examined by comparing their levels between the different body fluids. Detailed data are presented for each studied biomarker in [Supplements 1](#SM1){ref-type="supplementary-material"}--[6](#SM6){ref-type="supplementary-material"} as a correlation matrix.

Bivariate correlations between the various biomarkers in the different body fluids for the total cohort are shown in [Figure 3](#F3){ref-type="fig"}. Significant biomarker correlations in AF were: BNP-NTproBNP (*p* \< 0.01), Copeptin-NTproBNP (*p* \< 0.01), Copeptin-MRproADM (*p* = 0.01), Copeptin-MRproANP (*p* = 0.03), BNP-MRproANP (*p* = 0.03), MRproADM-NTproBNP (*p* = 0.03), hsTnI-MRproANP (*p* = 0.04). In MATB significant correlations were: MRproANP-NTproBNP (*p* \< 0.01), hsTnI-NTproBNP (*p* \< 0.01), MRproADM-MRproANP (*p* \< 0.01), BNP-NTproBNP (*p* \< 0.01), BNP-MRproANP (*p* \< 0.01), hsTnI-MRproANP (*p* \< 0.01), MRproADM-NTproBNP (*p* \< 0.01), Copeptin-hsTnI (*p* = 0.03), Copeptin-MRproANP (*p* = 0.42). In UAB significant correlations were: BNP-NTproBNP (*p* \< 0.01), MRprANP-NTproBNP (*p* \< 0.01), hsTnI-NTproBNP (*p* \< 0.01), BNP-MRproANP (*p* \< 0.01), Copeptin-MRproANP (*p* \< 0.01), BNP-MRproADM (*p* \< 0.05). In UVB significant correlations were: BNP-NTproBNP (*p* \< 0.01), MRprANP-NTproBNP (*p* \< 0.01), BNP-MRproANP (*p* \< 0.01), MRprADM-MRproANP (*p* \< 0.01), NTproBNP-MRproADM (*p* \< 0.01), hsTnI-MRproANP (*p* \< 0.01), BNP-MRproADM (*p* = 0.01), Copeptin-hsTnI (*p* = 0.03).

![Correlation matrix shows bivariate correlations between the six analyzed biomarkers in four different body fluids as scatterplots and correlation coefficients (Spearman\'s rho). The superimposed curves shown in the diagonal center axis represent frequency curves for individual values in the individual body fluids. The four examined body fluids are color coded as follows: amniotic fluid (AF), green; maternal blood (MATB), orange; umbilical arterial blood (UAB), blue; and umbilical venous blood (UVB), purple. The examined biomarkers were high-sensitive troponin I (hsTnI \[pg/mL\]), brain natriuretic peptide (BNP \[pg/mL\]), N-terminal pro-brain natriuretic peptide (NTproBNP \[pg/mL\]), midregional pro-atrial natriuretic peptide (MRproANP \[pmol/L\]), midregional pro-adrenomedullin (MRproADM \[nmol/L\]), and copeptin (COPT \[pmol/L\]). The database consisted of 189 neonates and their mothers.](fped-07-00271-g0003){#F3}

Biomarker Levels and Reference Values in Primary Cesarean Deliveries of Full-Term Singletons
--------------------------------------------------------------------------------------------

Biomarker levels and reference values are shown in [Table 3](#T3){ref-type="table"}. Reference values at the time of delivery are provided as percentiles in [Table 4](#T4){ref-type="table"}.

###### 

Percentiles for cardiovascular biomarkers in different body fluids in term singleton deliveries.

  **Biomarker**         **Fluid**   **Percentiles**                                                            
  --------------------- ----------- ----------------- -------- -------- -------- --------- --------- --------- ----
  MRproADM \[nmol/L\]   UAB         0.56              0.63     0.82     0.88     1.02      1.13      2.11      22
                        UVB         0.71              0.76     0.86     0.95     1.05      1.18      1.36      65
                        AF          0.69              0.93     2.32     2.80     3.50      4.51      5.02      37
                        MATB        0.65              0.74     0.88     1.10     1.42      1.62      2.17      77
  MRproANP \[pmol/L\]   UAB         113.55            142.19   170.53   214.23   261.90    336.66    375.04    48
                        UVB         144.01            151.06   173.66   216.03   259.81    340.04    387.39    86
                        AF          0.00              0.00     0.00     0.00     3.82      6.88      13.13     37
                        MATB        24.48             27.99    38.86    50.67    65.67     90.21     108.20    87
  BNP \[pg/mL\]         UAB         1.72              2.74     10.08    14.60    35.25     66.87     75.98     21
                        UVB         10.00             10.00    12.65    22.08    31.56     41.32     76.85     66
                        AF          1.36              2.87     4.56     7.15     10.58     14.67     25.09     38
                        MATB        0.00              0.00     0.00     6.20     18.23     34.53     48.31     77
  NTproBNP \[pg/mL\]    UAB         259.84            388.89   547.39   765.48   1102.63   1515.55   1819.50   48
                        UVB         369.62            397.81   597.91   816.45   1273.63   1743.40   2233.15   86
                        AF          31.54             41.01    52.92    72.03    108.50    129.04    212.10    37
                        MATB        11.92             17.49    26.95    44.40    70.89     130.03    149.75    87
  Copeptin \[pmol/L\]   UAB         5.02              5.49     12.34    46.17    302.76    500.00    1094.72   46
                        UVB         3.06              3.43     3.93     5.54     13.02     53.25     138.73    87
                        AF          2.79              2.99     6.12     9.97     13.55     31.44     46.75     38
                        MATB        1.68              2.18     3.17     4.61     7.76      20.18     38.64     86
  HsTnI \[pg/mL\]       UAB         2.36              2.60     4.98     6.20     9.23      23.66     69.89     45
                        UVB         2.15              2.65     3.58     5.60     8.59      13.61     31.72     86
                        AF          0.00              0.00     0.09     0.45     1.81      3.54      5.16      38
                        MATB        0.61              0.99     1.55     2.50     3.95      5.82      7.09      87

*UVB, umbilical venous blood; UAB, umbilical arterial blood; AF, amniotic fluid; MATB, maternal blood. The database consisted of n = 91 neonates and their mothers*.

Discussion {#s4}
==========

The main novelty of this study was combined analysis of linked biomarker sample sets from individual pregnancies in the mother and child at the time of delivery, including AF, UAB, UVB, and MATB. Additionally, we calculated reference values for singleton, full-term cesarean deliveries for six different biomarkers (MRproADM, MRproANP, BNP, NTproBNP, copeptin, hsTnI) in these four different body fluids.

Theoretical considerations on production and clearance of these biomarkers may be derived using the simultaneous distribution pattern of individual biomarkers over different fetal and maternal fluid compartments. The highest levels of MRproADM were observed in AF, followed by MATB, and the lowest levels were in fetal blood. Additionally, MRproADM levels were positively correlated with UVB and UAB. This biomarker pattern may support a placental source of this biomarker. Alternatively, fetal renal excretion into the AF might have occurred. Higher MRproADM levels in multiple pregnancies with a relatively larger amount of total placental tissue, as shown in our study ([Table 5](#T5){ref-type="table"}), and lower levels in placental insufficiency ([@B18]) support a placental origin of MRproADM.

###### 

Factors influencing biomarker levels: gestational age, labor, multiple gestation (Spearman\'s correlation, rho).

  **Biomarker**   **Fluid**   **Gestational age**                         **Exposure to labor**                       **Multiple gestation**                      **N**
  --------------- ----------- ------------------------------------------- ------------------------------------------- ------------------------------------------- -------
  MRproADM        UAB         −0.548[^\*\*^](#TN2){ref-type="table-fn"}   0.172                                       0.378[^\*^](#TN1){ref-type="table-fn"}      42
                  UVB         −0.328[^\*\*^](#TN2){ref-type="table-fn"}   0.180[^\*^](#TN1){ref-type="table-fn"}      0.126                                       134
                  AF          0.048                                       0.040                                       −0.194                                      63
                  MATB        −0.126                                      0.010                                       0.383[^\*\*^](#TN2){ref-type="table-fn"}    145
  MRproANP        UAB         −0.555[^\*\*^](#TN2){ref-type="table-fn"}   −0.207[^\*^](#TN1){ref-type="table-fn"}     0.453[^\*\*^](#TN2){ref-type="table-fn"}    98
                  UVB         −0.453[^\*\*^](#TN2){ref-type="table-fn"}   −0.205[^\*\*^](#TN2){ref-type="table-fn"}   0.334[^\*\*^](#TN2){ref-type="table-fn"}    173
                  AF          −0.278[^\*^](#TN1){ref-type="table-fn"}     0.166                                       0.291[^\*^](#TN1){ref-type="table-fn"}      64
                  MATB        −0.015                                      0.180[^\*^](#TN1){ref-type="table-fn"}      0.199[^\*^](#TN1){ref-type="table-fn"}      160
  BNP             UAB         −0.479[^\*\*^](#TN2){ref-type="table-fn"}   −0.073                                      0.497[^\*\*^](#TN2){ref-type="table-fn"}    36
                  UVB         −0.163                                      −0.160                                      0.063                                       137
                  AF          −0.484[^\*\*^](#TN2){ref-type="table-fn"}   0.020                                       0.526[^\*\*^](#TN2){ref-type="table-fn"}    66
                  MATB        0.074                                       0.080                                       0.100                                       145
  NTproBNP        UAB         −0.289[^\*\*^](#TN2){ref-type="table-fn"}   0.025                                       0.057                                       97
                  UVB         −0.320[^\*\*^](#TN2){ref-type="table-fn"}   −0.049                                      0.106                                       174
                  AF          −0.460[^\*\*^](#TN2){ref-type="table-fn"}   0.118                                       0.385[^\*\*^](#TN2){ref-type="table-fn"}    64
                  MATB        0.044                                       0.395[^\*\*^](#TN2){ref-type="table-fn"}    0.116                                       160
  Copeptin        UAB         0.460[^\*\*^](#TN2){ref-type="table-fn"}    0.561[^\*\*^](#TN2){ref-type="table-fn"}    −0.401[^\*\*^](#TN2){ref-type="table-fn"}   93
                  UVB         0.260[^\*\*^](#TN2){ref-type="table-fn"}    0.653[^\*\*^](#TN2){ref-type="table-fn"}    −0.137                                      175
                  AF          −0.237                                      0.070                                       0.149                                       65
                  MATB        0.131                                       0.251[^\*\*^](#TN2){ref-type="table-fn"}    0.057                                       159
  hsTnI           UAB         −0.177                                      0.244[^\*^](#TN1){ref-type="table-fn"}      0.135                                       91
                  UVB         −0.136                                      0.158[^\*^](#TN1){ref-type="table-fn"}      0.081                                       174
                  AF          0.081                                       0.155                                       −0.080                                      66
                  MATB        0.025                                       0.294[^\*\*^](#TN2){ref-type="table-fn"}    0.052                                       160

UVB, umbilical venous blood; UAB, umbilical arterial blood; AF, amniotic fluid; MATB, maternal blood; Spearman\'s correlation, rho. Significance level of correlation:

*p \< 0.05*,

*p \< 001. The database consisted of n = 189 neonates and their mothers*.

Levels of the natriuretic peptides MRproANP, BNP, and NTproBNP were higher in fetal than in MATB ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). In paired UVB and UAB samples, natriuretic peptides (MRproANP, BNP, and NTproBNP) were correlated ([Figure 3](#F3){ref-type="fig"}). Levels of MRproANP and NTproBNP were higher in UVB than in UAB ([Figure 2](#F2){ref-type="fig"}). This distribution of natriuretic peptides suggests fetal production of the precursor molecules pro-BNP ([@B7]) and pro-ANP ([@B19], [@B20]), and subsequent placental cleavage of MRproANP and NTproBNP from the precursors. These findings support the hypothesis that the fetus is the main source of natriuretic peptides in the fetal circulation. There was an inverse correlation between fetal natriuretic peptide levels and gestational age ([Table 5](#T5){ref-type="table"}, [Supplements 1](#SM1){ref-type="supplementary-material"}--[6](#SM6){ref-type="supplementary-material"}), consistent with our previous study ([@B17]). The fetal circulation and AF production in midgestation appear to require physiologically elevated natriuretic peptide levels. These fetal natriuretic peptide levels are as high as those in adults with New York Heart Association class IV cardiac insufficiency ([@B12], [@B13]).

In our study, copeptin appeared to be produced by the fetus during labor. Copeptin levels in UAB were higher than those in UVB. Neonates who were exposed to labor ([Table 5](#T5){ref-type="table"}) had much higher copeptin levels than those born by elective cesarean section. In our study, fetal copeptin levels were higher than maternal copeptin levels. Interestingly, previous studies on copeptin have shown higher copeptin levels in the fetus than in the mother in secondary cesarean sections performed for fetal distress ([@B21], [@B22]). Furthermore, copeptin levels are lower in the fetus than in the mother in cesarean sections performed for reasons other than fetal distress ([@B21], [@B22]). Copeptin may be used as an indicator for fetal distress ([@B21]--[@B23]).

The distribution pattern for hsTnI appeared compatible with placental biomarker clearance between UAB and UVB and/or a transfer of hsTnI to MATB ([Figures 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

Biomarkers appear to be regulated independently in the fetal and maternal circulations. Except for NTproBNP, all examined biomarkers showed a weak positive correlation between UVB and MATB ([Supplements 1](#SM1){ref-type="supplementary-material"}--[6](#SM6){ref-type="supplementary-material"}). If a biomarker is present at higher levels in the fetus than in the mother and there is a positive feto-maternal correlation, feto-maternal transfer of that biomarker may occur. Alternatively, a feto-maternal correlation might be caused by placental or hormonal effects on the mother and child, affecting biomarker levels in the same direction.

We calculated reference values for biomarkers in healthy term pregnancies in AF, UAB, UVB, and MATB. In addition to previous literature data on the examined biomarkers ([@B1]--[@B11], [@B18]--[@B26]), this study combined neonatal and maternal biomarker levels in different body fluids, including AF. We did not examine the prognostic relevance of individual biomarkers ([@B23], [@B27]). The factors of gestational age, multiple pregnancies, and exposure to labor did affect biomarker levels ([Table 5](#T5){ref-type="table"}). Therefore, we limited reference value calculation to full-term singletons who were delivered by elective cesarean section.

There are several potential limitations in our study. Because of the necessity to obtain informed consent for sample collection before delivery, neonates who were delivered by elective cesarean section are over-represented in the studied sample cohort (68%) compared with the local cesarean section rate of \<30%. AF can easily be obtained in elective cesarean section, but is difficult to obtain during normal vaginal delivery. Therefore, we chose to provide reference values for the well-defined subgroup of healthy, full-term, singleton, elective cesarean deliveries to avoid bias by delivery mode, gestational age, and multiple pregnancies.

Samples were collected and analyzed in several batches. This might have caused analytical bias between separate occasions of measurement. The commercially available kits that we used have not been tested for analyzing AF, which might have caused methodical bias. In several BNP samples, the lower limit of the analysis was set to 10 units (see [Table 3](#T3){ref-type="table"}), as recommended by the manufacturer. This limit aggravated the skewness of distribution of BNP levels. The timing of maternal blood samples (taken before or after delivery), and thus the effect of labor ([@B1], [@B2]) or intravenous hydration during cesarean section, on maternal biomarker levels may have affected maternal biomarker levels. Despite this bias, our data support a general difference between maternal and fetal biomarker levels. The amount of blood and AF that were obtained was not sufficient to analyze all examined biomarkers in all feto-maternal matched samples, which resulted in a reduction in sample size. Because unclamped umbilical blood flow may continue several minutes after delivery ([@B28]--[@B30]), variation in delayed umbilical cord clamping might affect fetal biomarker levels.

Conclusion {#s5}
==========

The main novelty of this study was combined analysis of linked biomarker sample sets of four different body fluids in healthy pregnancies at the time of delivery. Levels of six different cardiovascular biomarkers were measured, including MRproADM, MRproANP, BNP, NTproBNP, copeptin, and hsTnI. The observed biomarker distribution patterns suggest that most cardiovascular biomarkers in the fetal circulation are of primary fetal origin. Biomarker reference values for singleton, full-term, cesarean deliveries are provided.
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Contribution to the Field Statement {#s9}
===================================

A biomarker in medicine is a measurable parameter that can be used to assess the physiological or pathological state of an organism. Several proteins in the blood stream can be used as biomarkers. Cardiovascular biomarkers are used to assess the cardiac and circulatory situation in adult medicine. These biomarkers are also relevant in perinatal maternal and fetal physiology. Therefore, in the field of cardiovascular biomarkers, there is an interesting overlap between neonatology, obstetrics, and cardiology. This study analyzed six different cardiovascular biomarkers (derivate of adrenomedullin, three different natriuretic peptides, copeptin, and troponin) in four different body fluids (amniotic fluid, umbilical arterial and umbilical venous blood, and maternal blood) at the time of delivery. The distribution pattern of these biomarkers between maternal and fetal fluids is described. Reference values for the different biomarkers in singleton, full-term pregnancies are provided for these biomarkers in different body fluids. Most biomarkers showed higher levels in fetal than in maternal blood. Our data suggest that the source of these biomarkers in the fetal circulation is the fetus. Adrenomedullin, which was highest in amniotic fluid, might originate from a placental source or from fetal urine, which is the main source of amniotic fluid.
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Body fluids: AF

:   amniotic fluid

MATB

:   maternal blood

UAB

:   umbilical arterial blood

UVB

:   umbilical venous blood

Biomarker: BNP

:   brain natriuretic peptide

hsTnI

:   high-sensitive troponin I

MRproADM

:   midregional pro-adrenomedullin

MRproANP

:   midregional pro-atrial natriuretic peptide

NTproBNP

:   N-terminal pro-brain natriuretic peptide

Other abbreviations: CV

:   coefficient of variation

HELLP syndrome

:   hemolysis, elevated liver enzymes low platelets

LoD

:   limit of detection.
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